Global Thyroid Disorder Market to Take Off by 2030

The global market for diagnosing and treating thyroid gland disorders is projected to grow from US$16.3 billion in 2025 to US$21.0 billion by 2030, according to BCC Research. Growth is being driven by rising disease prevalence, technological innovation, and expanded screening programs in key markets, including Mexico. The market is expected to grow at a compound annual growth rate of 5.2% through the end of the decade.

“Innovations in AI diagnostics, personalized molecular testing, and advanced surgical technologies are reshaping the global thyroid disorder market, driving improved detection, treatment, and patient outcomes,” says BCC Research.

The report attributes the projected growth to several converging factors, including rising prevalence of thyroid-related conditions such as hypothyroidism, hyperthyroidism, and thyroid cancer. These conditions are becoming more common due to iodine deficiency, aging populations, and lifestyle changes. At the same time, increased health screenings and improved diagnostic tools are facilitating earlier detection, especially of thyroid cancers, which remain a leading growth driver.

Policy initiatives and awareness campaigns by governments and health organizations are also supporting early diagnosis and treatment adherence. Combined with the rise of personalized medicine, where treatment is tailored based on genetic and hormonal profiles, these developments are expected to reinforce market expansion through 2030.

According to BCC Research, the largest segment is hypothyroidism, and North America is the most dominant region in terms of market share. The report identifies Mexico as a key market in Latin America, with rising thyroid disorder diagnoses linked to increased public health initiatives and urban lifestyle shifts. The country has also joined regional strategies to expand access to early diagnostics and promote awareness through national screening programs. Mexico’s role is further reinforced by its growing healthcare infrastructure and participation in clinical trials.

Startups are also contributing to the landscape. Immunovant, for example, reported promising Phase 2a results in 2024 for batoclimab in treating Graves’ disease, addressing an unmet need among patients unresponsive to anti-thyroid drugs. That same year, Azurity Pharmaceuticals launched Adthyza, a new natural desiccated thyroid drug, marking one of the few brand-name entrants in this space in recent years.

Major players in the market include Abbott, AbbVie, Amgen, AstraZeneca, Roche, Pfizer, Merck, Sanofi, Siemens Healthineers, and Terumo.